Cartesian Therapeutics News

Express News | Oppenheimer Maintains Outperform on Cartesian Therapeutics, Maintains $50 Price Target

BenzingaJun 14 13:30 ET

Cartesian Therapeutics Announces New Employment Inducement Grant

GAITHERSBURG, Md., June 06, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune

GlobeNewswireJun 6 07:05 ET

Express News | Cartesian Therapeutics Inc : Oppenheimer Initiates Coverage With Outperform Rating; Price Target $50

ReutersJun 4 08:32 ET

Cartesian Therapeutics Price Target Announced at $50.00/Share by Oppenheimer

Cartesian Therapeutics Price Target Announced at $50.00/Share by Oppenheimer

Dow JonesJun 4 08:16 ET

Oppenheimer Initiates Cartesian Therapeutics With Outperform Rating, $50 Price Target

Cartesian Therapeutics (RNAC) has an average rating of buy and price targets ranging from $38 to $54, according to analysts polled by Capital IQ.

MT NewswiresJun 4 06:51 ET

Mizuho Securities Maintains Cartesian Therapeutics(RNAC.US) With Buy Rating, Cuts Target Price to $40

Mizuho Securities analyst Uy Ear maintains $Cartesian Therapeutics(RNAC.US)$ with a buy rating, and adjusts the target price from $90 to $40.According to TipRanks data, the analyst has a success rate

moomoo NewsMay 24 07:33 ET

Express News | Cartesian Therapeutics Inc : Mizuho Initiates With Buy Rating and $40 Price Target

ReutersMay 24 05:35 ET

Buy Rating Affirmed for Cartesian Therapeutics Amidst Promising Clinical Advancements and Strategic Positioning

TipRanksMay 24 01:52 ET

H.C. Wainwright Maintains Cartesian Therapeutics(RNAC.US) With Buy Rating, Maintains Target Price $54

H.C. Wainwright analyst Mitchell Kapoor maintains $Cartesian Therapeutics(RNAC.US)$ with a buy rating, and maintains the target price at $54.According to TipRanks data, the analyst has a success rate

moomoo NewsMay 23 06:32 ET

Cartesian Stock Climbs 8% on FDA Regenerative Therapy Designation

Seeking AlphaMay 22 10:57 ET

Express News | Cartesian Therapeutics Shares up 8.3% on Fda's 'rmat' Tag for Autoimmune Disorder Treatment

ReutersMay 22 09:44 ET

Express News | Cartesian- on Track to Post Topline Data From Phase 2B Randomized, Placebo-Controlled Trial of Descartes-08 in Patients With Mg in Mid-2024

ReutersMay 22 07:02 ET

Express News | Cartesian Therapeutics Secures FDA Regenerative Medicine Advanced Therapy Designation For Descartes-08 For Treatment Of Myasthenia Gravis

BenzingaMay 22 07:01 ET

Express News | Cartesian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (Rmat) Designation for Descartes-08 for the Treatment of Myasthenia Gravis

ReutersMay 22 07:00 ET

Cartesian Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

GAITHERSBURG, Md., May 13, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today

GlobeNewswireMay 13 16:30 ET

Cartesian Therapeutics Inc (RNAC) Reports Q1 2024 Earnings: A Detailed Financial and ...

Yahoo FinanceMay 10 15:12 ET

Buy Rating Affirmed for Cartesian Therapeutics on Strong Clinical Progress and Strategic Expansion

TipRanksMay 10 01:31 ET

Express News | HC Wainwright & Co. Reiterates Buy on Cartesian Therapeutics, Maintains $54 Price Target

BenzingaMay 9 15:24 ET

Cartesian Therapeutics Price Target Maintained With a $42.00/Share by Needham

Cartesian Therapeutics Price Target Maintained With a $42.00/Share by Needham

Dow JonesMay 8 11:50 ET

Needham Reiterates Buy on Cartesian Therapeutics, Maintains $42 Price Target

Needham analyst Gil Blum reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $42 price target.

BenzingaMay 8 11:40 ET